AKAO 2018 Proxy Statement

10 Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease award. Dr. Fischbach received his Ph.D. as a John and Fannie Hertz Foundation Fellow in Chemistry from Harvard in 2007 and earned his A.B. in Biochemistry from Harvard. Dr. Fischbach brings to our board of directors significant knowledge and experience in biotechnology. John W. Smither . Mr. Smither has served on our board of directors since December 2013. Mr. Smither has served as Chief Financial Officer of Sienna Biopharmaceuticals, Inc., a biotechnology company, since April2018. From November 2017 to April 2018, Mr. Smither served as Interim CFO for Kite Pharma, a subsidiary of Gilead Sciences. From January 2016 to July 2017, Mr. Smither served as Chief Financial Officer of Unity Biotechnology, Inc., a biotechnology company. From January 2016 to March 2017, Mr. Smither served as Chief Financial Officer of Sienna Biopharmaceuticals. Mr. Smither served as Chief Financial Officer of KYTHERA Biopharmaceuticals, Inc., a publicly traded biotechnology company, from November 2007 until it was acquired by Allergan, Inc. in October 2015. From 1998 to 2007, Mr. Smither held various positions at Amgen Inc., a publicly traded biotechnology company, including Executive Director of Corporate Accounting, Vice President of Finance and Administration of Amgen’s European Division, and Head of Internal Audit. Prior to joining Amgen, Mr. Smither served as an Audit Partner at Ernst & Young LLP, a public accounting firm. Following his time at Ernst & Young LLP, Mr. Smither served as the Chief Financial Officer of several early stage companies. Mr. Smither holds a B.S. in Business Administration from California State University, Los Angeles. Mr. Smither is a Certified Public Accountant (inactive) and a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants and Financial Executives International. Mr. Smither brings to our board of directors his substantive expertise in finance and accounting, and his extensive experience in the biotechnology industry. THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE ELECTION OF EACH CLASS I NOMINEE NAMED ABOVE Directors Continuing in Office Until the 2019 Annual Meeting of Stockholders Halley E. Gilbert . Ms. Gilbert has served on our board of directors since January 2017. Since 2008, Ms. Gilbert has served as Senior Vice President, Chief Legal Officer of Ironwood Pharmaceuticals, Inc., a publicly- traded biotechnology company. Prior to joining Ironwood, Ms. Gilbert was Vice President, Deputy General Counsel at Cubist Pharmaceuticals, Inc. (“Cubist”) from 2002 to 2008, where she supported the launch of Cubist’s first acute care antibiotic, and she served as Corporate Counsel at Genzyme Corp. from 1999 to 2001. Ms. Gilbert began her career at Skadden, Arps, Slate, Meagher & Flom LLP, where she specialized in mergers and acquisitions and securities law. Ms. Gilbert holds a J.D. from Northwestern University School of Law and a B.A. from Tufts University. Ms. Gilbert brings to our board of directors her experience with launching new biopharma products and establishing robust risk management and compliance programs at biopharma companies. Kenneth J. Hillan, M.B., Ch.B. Dr. Hillan has served on our board of directors since October 2011. Dr. Hillan serves as our President, R&D and President of Achaogen. Previously, Dr. Hillan served as our Chief Medical Officer from April 2011 until July 2014, served as our President from October 2011 to February 2017 and served as our Chief Executive Officer from October 2011 to January 2018. Prior to joining Achaogen, from 1994 to April 2011, Dr. Hillan was employed at Genentech, where he was responsible for numerous successful drug approvals and led the medical and scientific strategies for Genentech’s Immunology, Tissue Growth and Repair drug portfolio. For Genentech, he served in a number of key leadership positions in research and development, including Senior Vice President Clinical Development, Inflammation, Vice President Immunology, Tissue Growth and Repair, Vice President Development Sciences and Vice President Research Operations and Pathology. Dr. Hillan also previously served as Senior Vice President and head of Clinical Development and Product Development Strategy in Asia- Pacific for F. Hoffmann-La Roche AG in Shanghai, China. Dr. Hillan has served on the board of Zymeworks, Inc., a publicly traded biotechnology company, since February 2017. Dr. Hillan served on the board of directors of Relypsa, Inc., a publicly traded biotechnology company, from June 2014 to September 2016 when it was acquired